



NEWS RELEASE

## Impax to Present at the 37th Annual Raymond James Institutional Investors Conference

3/1/2016

HAYWARD, Calif., March 1, 2016 /PRNewswire/ -- **Impax Laboratories, Inc.** (NASDAQ: IPXL) today announced that the Company will present a corporate overview at the 37th Annual Raymond James Institutional Investors Conference on Monday, March 7, 2016 at 10:25 a.m. Eastern Standard Time. The conference will be held in Orlando, FL.

Logo - <http://photos.prnewswire.com/prnh/20150310/180590LOGO>

Individuals may listen to the live or an archived presentation made at the conference, which will be posted in the investor relations section of the Company's web site at [www.impaxlabs.com](http://www.impaxlabs.com). This presentation will be archived on the Company's web site for 90 days.

### About Impax Laboratories, Inc.

Impax Laboratories, Inc. (Impax) is a specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Impax Generics division and markets its branded products through the Impax Specialty Pharma division. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams, and ointments. For more information, please visit the Company's Web site at: [www.impaxlabs.com](http://www.impaxlabs.com).

### Company Contacts:

Mark Donohue

Investor Relations and Corporate Communications

(215) 558-4526

**[www.impaxlabs.com](http://www.impaxlabs.com)**

To view the original version on PR Newswire, visit: **<http://www.prnewswire.com/news-releases/impax-to-present-at-the-37th-annual-raymond-james-institutional-investors-conference-300228332.html>**

SOURCE Impax Laboratories, Inc.